News Digest / Ticker: RGNX

Ticker: RGNX

09:23am, Tuesday, May 13, 2025

Regenxbio Soars 7.2% on FDA Acceptance of Groundbreaking Gene Therapy for Hunter Syndrome

Regenxbio Inc. (NASDAQ: RGNX) surged 7.2% in premarket after the FDA accepted its BLA for RGX-121, a gene therapy for MPS II. With a target action date of Nov 9, 2025, this potential breakthrough could reshape treatment for Hunter syndrome.